American Headache Society Annual Scientific Meeting 2019

The Annual Scientific Meeting of the American Headache Society, held July 11-14, 2019 in Philadelphia, Pennsylvania, is a prime location for the dissemination of the latest and most up-to-date research and scientific advances underlying the practice of headache medicine. The meeting is designed for physicians, psychologists, scientists, researchers, physician assistants, nurse practitioners, and other health professionals involved in the care of patients with head, neck, and orofacial pain.

The professor of neurology, neurotherapeutics, and ophthalmology at UT Southwestern discussed the need to better coordinate care between providers when telemedicine is being utilized in headache and migraine care.
The director of the MedStar Georgetown Headache Center spoke about the higher-than-desired rates of opioid prescriptions for patients with migraine, and how new treatment options and provider education can help lower those numbers.
The director of the Orange County Migraine and Headache Center spoke about the adherence issues in acute migraine treatment and how the safety profile of investigational medications such as rimegepant and ubrogepant suggests they may be able to address them.
The director of headache medicine and chief of general neurology at Yale Medicine spoke about the significance of having CGRP inhibitors in migraine treatment, and how eptinezumab fits into the treatment landscape.
The clinical professor of neurology at Albert Einstein College of Medicine spoke about the trends revealed by the OVERCOME study, and how this data can be used to improve the management of the millions of patients with migraine in the US.
The director of the Montefiore Headache Center and professor of neurology at Albert Einstein College of Medicine spoke about the results of an analysis of eptinezumab’s effect on the severity of migraine and its impact on patients’ lives.
The professor of neurology, neurotherapeutics, and ophthalmology at UT Southwestern spoke about the potential of telemedicine in headache medicine, as well as the findings from a single-center, 45-patient study.
The director of the MedStar Georgetown Headache Center spoke about ubrogepant’s long-term safety and efficacy and its potential to fill the large gap that remains in acute migraine care.